Literature DB >> 8415631

Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation.

R R Berges1, Y Furuya, L Remington, H F English, T Jacks, J T Isaacs.   

Abstract

Androgen ablation induces programmed death of androgen-dependent prostatic glandular cells, resulting in fragmentation of their genomic DNA and the cells themselves into apoptotic bodies. Twenty percent of prostatic glandular cells undergo programmed death per day between day 2 and 5 after castration. During this same period, < 1% of prostatic glandular cells enter the S phase of the cell cycle, documenting that > 95% of these die in G0. During the programmed death of these G0 glandular cells, a futile DNA repair process is induced secondary to the DNA fragmentation. This futile DNA repair is not required, however, since inhibition of this process by > 90% with an appropriately timed hydroxy-urea dosing regimen had no effect upon the extent of the programmed death of these cells after castration. Likewise, p53 gene expression is not required since the same degree of cell death occurred in prostates and seminal vesicles after castration of wild-type and p53-deficient mice.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415631      PMCID: PMC47470          DOI: 10.1073/pnas.90.19.8910

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  "Thymineless" death in androgen-independent prostatic cancer cells.

Authors:  N Kyprianou; J T Isaacs
Journal:  Biochem Biophys Res Commun       Date:  1989-11-30       Impact factor: 3.575

2.  Thymocyte apoptosis induced by p53-dependent and independent pathways.

Authors:  A R Clarke; C A Purdie; D J Harrison; R G Morris; C C Bird; M L Hooper; A H Wyllie
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

3.  p53 is required for radiation-induced apoptosis in mouse thymocytes.

Authors:  S W Lowe; E M Schmitt; S W Smith; B A Osborne; T Jacks
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

4.  p53-mediated cell death: relationship to cell cycle control.

Authors:  E Yonish-Rouach; D Grunwald; S Wilder; A Kimchi; E May; J J Lawrence; P May; M Oren
Journal:  Mol Cell Biol       Date:  1993-03       Impact factor: 4.272

5.  Deletion of cells by apoptosis during castration-induced involution of the rat prostate.

Authors:  J F Kerr; J Searle
Journal:  Virchows Arch B Cell Pathol       Date:  1973-06-25

6.  [Histological and cell kinetic studies of the growth of rat prostate of various ages].

Authors:  R Stiens; B Helpap
Journal:  Acta Anat (Basel)       Date:  1981

7.  High levels of p53 protein in UV-irradiated normal human skin.

Authors:  P A Hall; P H McKee; H D Menage; R Dover; D P Lane
Journal:  Oncogene       Date:  1993-01       Impact factor: 9.867

8.  [Regressive change in the rat prostate after castration. A study using histology, morphometrics and autoradiography with special reference to apoptosis (author's transl)].

Authors:  R Stiens; B Helpap
Journal:  Pathol Res Pract       Date:  1981-07       Impact factor: 3.250

9.  Castration-induced changes in morphology, androgen levels, and proliferative activity of human prostate cancer tissue grown in athymic nude mice.

Authors:  W M van Weerden; A van Kreuningen; N M Elissen; M Vermeij; F H de Jong; G J van Steenbrugge; F H Schröder
Journal:  Prostate       Date:  1993       Impact factor: 4.104

Review 10.  Androgen regulation of programmed death of normal and malignant prostatic cells.

Authors:  J T Isaacs; P I Lundmo; R Berges; P Martikainen; N Kyprianou; H F English
Journal:  J Androl       Date:  1992 Nov-Dec
View more
  36 in total

1.  Consequences of CK2 signaling to the nuclear matrix.

Authors:  S Yu; H Wang; A Davis; K Ahmed
Journal:  Mol Cell Biochem       Date:  2001-11       Impact factor: 3.396

Review 2.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

Review 3.  Endothelin receptor antagonists.

Authors:  Joel B Nelson
Journal:  World J Urol       Date:  2005-01-15       Impact factor: 4.226

Review 4.  Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer.

Authors:  Ana Aparicio; Robert B Den; Karen E Knudsen
Journal:  Nat Rev Urol       Date:  2011-08-02       Impact factor: 14.432

5.  Tissue changes in senescent gerbil prostate after hormone deprivation leads to acquisition of androgen insensitivity.

Authors:  Silvana G P Campos; Bianca F Gonçalves; Wellerson R Scarano; Lara S Corradi; Fernanda C A Santos; Ana M G Custodio; Patricia S L Vilamaior; Rejane M Góes; Sebastião R Taboga
Journal:  Int J Exp Pathol       Date:  2010-10       Impact factor: 1.925

6.  p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle.

Authors:  T Haapajärvi; K Pitkänen; M Tsubari; M Laiho
Journal:  Mol Cell Biol       Date:  1997-06       Impact factor: 4.272

Review 7.  The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis.

Authors:  Joanne N Davis; Mark L Day
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

8.  Protein B23/nucleophosmin/numatrin nuclear dynamics in relation to protein kinase CK2 and apoptotic activity in prostate cells.

Authors:  Guixia Wang; Yunqian Pan; Kashif A Ahmad; Khalil Ahmed
Journal:  Biochemistry       Date:  2010-05-11       Impact factor: 3.162

9.  Apoptosis in erythroid progenitors deprived of erythropoietin occurs during the G1 and S phases of the cell cycle without growth arrest or stabilization of wild-type p53.

Authors:  L L Kelley; W F Green; G G Hicks; M C Bondurant; M J Koury; H E Ruley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.

Authors:  Puranik Purushottamachar; Abhijit M Godbole; Lalji K Gediya; Marlena S Martin; Tadas S Vasaitis; Andrew K Kwegyir-Afful; Senthilmurugan Ramalingam; Zeynep Ates-Alagoz; Vincent C O Njar
Journal:  J Med Chem       Date:  2013-06-07       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.